Tasimelteon

Tasimelteon
Clinical data
Trade names	Hetlioz, Hetlioz LQ
AHFS/Drugs.com	Monograph
MedlinePlus	a615004
License data	EU EMA: by INN; US DailyMed: Tasimelteon;
Dependence; liability	Low
Routes of; administration	By mouth
ATC code	N05CH03 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	not determined in humans
Protein binding	89–90%
Metabolism	extensive liver, primarily CYP1A2 and CYP3A4-mediated
Elimination half-life	0.9–1.7 h / 0.8–5.9 h (terminal)
Excretion	80% in urine, 4% in feces
Identifiers
	IUPAC name (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide;
CAS Number	609799-22-6 ;
PubChem CID	10220503;
IUPHAR/BPS	7393;
DrugBank	DB09071 ;
ChemSpider	8395995 ;
UNII	SHS4PU80D9;
ChEBI	CHEBI:79042 ;
CompTox Dashboard (EPA)	DTXSID70209826 ;
ECHA InfoCard	100.114.889
Chemical and physical data
Formula	C15H19NO2
Molar mass	245.322 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2;
	InChI InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 ; Key:PTOIAAWZLUQTIO-GXFFZTMASA-N ;
	(what is this?) (verify)

Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA)^[3] in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD).^[4] In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon^[5] and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults,^[6] but not in the case of non-24 in sighted people.

The most common side effects include headache, somnolence, nausea (feeling sick) and dizziness.^[7]

^ Kim HK, Yang KI (December 2022). "Melatonin and melatonergic drugs in sleep disorders". Translational and Clinical Pharmacology. 30 (4): 163–171. doi:10.12793/tcp.2022.30.e21. PMC 9810491. PMID 36632077.
^ "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013. Archived from the original (PDF) on November 25, 2013.
^ "FDA transcript approval minutes" (PDF). FDA. November 14, 2013. Archived from the original (PDF) on May 8, 2014.
^ Food and Drug Administration (January 31, 2014). "FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder" (Press release). FDA. Archived from the original on February 2, 2014. Retrieved December 16, 2019.
^ "tasimelteon (Hetlioz) UKMi New Drugs Online Database". Archived from the original on June 29, 2016. Retrieved August 6, 2014.
^ "Hetlioz Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind". MarketWatch. 7 July 2015. Archived from the original on 9 July 2015. Retrieved 8 July 2015 – via PR Newswire.
^ Cite error: The named reference Hetlioz EPAR was invoked but never defined (see the help page).

[Yang2022-1] Kim HK, Yang KI (December 2022). "Melatonin and melatonergic drugs in sleep disorders". Translational and Clinical Pharmacology. 30 (4): 163–171. doi:10.12793/tcp.2022.30.e21. PMC 9810491. PMID 36632077.

[2] "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013. Archived from the original (PDF) on November 25, 2013.

[3] "FDA transcript approval minutes" (PDF). FDA. November 14, 2013. Archived from the original (PDF) on May 8, 2014.

[approval-4] Food and Drug Administration (January 31, 2014). "FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder" (Press release). FDA. Archived from the original on February 2, 2014. Retrieved December 16, 2019.

[5] "tasimelteon (Hetlioz) UKMi New Drugs Online Database". Archived from the original on June 29, 2016. Retrieved August 6, 2014.

[6] "Hetlioz Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind". MarketWatch. 7 July 2015. Archived from the original on 9 July 2015. Retrieved 8 July 2015 – via PR Newswire.

[Hetlioz_EPAR-7] Cite error: The named reference Hetlioz EPAR was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]

[7]